Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
Official title: A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
213
Start Date
2024-10-10
Completion Date
2027-10-14
Last Updated
2025-10-21
Healthy Volunteers
No
Conditions
Interventions
BMS-986484
Specified dose on specified days
Nivolumab
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Capecitabine
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Calcium folinate
Specified dose on specified days
Locations (11)
University of Arizona Cancer Center
Tucson, Arizona, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
START Midwest
Grand Rapids, Michigan, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
NEXT Oncology
San Antonio, Texas, United States
St Vincent's Hospital
Darlinghurst, New South Wales, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Local Institution - 0023
Chuo-ku, Tokyo, Japan
Local Institution - 0022
Kashiwa, Japan